Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature. (23rd March 2017)

• Record Type: Journal Article
• Authors: Webb, Kirsten C.; Harasimowicz, Magdalena; Janeczek, Monica; Speiser, Jodi; Swan, James; Tung, Rebecca
• Other Names: Jimbow Kowichi Academic Editor.
• Is Part Of: Case reports in dermatological medicine. Volume 2017(2017)
• Publication Date: 2017-03-23
• Subjects: Dermatology -- Periodicals; Skin -- Diseases -- Periodicals; 616.5005
• DOI: 10.1155/2017/9359086
• Languages: English
• ISSNs: 2090-6463

Abstract

Abstract : Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) used to treat imatinib-resistant chronic myelogenous leukemia (CML), as well as other Philadelphia chromosome-positive lymphoproliferative disorders. While the most commonly reported cutaneous side effects with this therapy include a morbilliform eruption, skin exfoliation, and skin irritation, pigmentary abnormalities have also been observed, albeit much more rarely. We present the case of a 72-year-old South Asian male with CML who presented with new-onset hypopigmentation of his face and scalp three years after a dose increase of dasatinib therapy, in the setting of newly discovered borderline hypovitaminosis D. Dasatinib and the other TKIs are believed to induce dyschromias via modulation of the c-kit receptor and its associated signaling pathway, which is involved in melanocyte survival, proliferation, and migration.